Sanofi, a French pharmaceutical company, is investing approximately 1.3 billion euros to build a new insulin production facility in Frankfurt's Höchst industrial park by 2029.

This significant investment is supported by the German federal government, the state government of Hesse, and the city of Frankfurt, although specific financial details remain undisclosed pending EU approval.

Hessian Prime Minister Boris Rhein and Economic Minister Kaweh Mansoori hailed the investment as a strong signal for Germany's pharmaceutical sector and a milestone for the country's medicine sovereignty and export strength.

Frankfurt's Mayor, Mike Josef, expressed that this investment strengthens the local economy and highlights the city's favorable conditions for businesses, securing additional industrial jobs.

Sanofi stated that this development will ensure a long-term supply of vital insulin for diabetes patients and enhance the resilience of the European supply chain.

Mansoori noted that the insulin production in Frankfurt will enhance Germany's healthcare resilience, addressing medication shortages amid ongoing supply chain issues.

The new facility will replace an existing production site in the Höchst district and is expected to employ several hundred skilled workers.

Sanofi's Frankfurt-Höchst site is one of its largest facilities, employing around 6,600 people and producing the diabetes medication Lantus, which generates significant annual revenue.

The new facility will position Hessen as a key center for insulin production in Europe, supported by over a century of expertise in the region.

This investment reflects a trend of increasing investments by pharmaceutical companies in Germany, with other firms like Eli Lilly and Daiichi-Sankyo also announcing significant commitments.

Recent reports had indicated Sanofi might relocate insulin production to France, but the confirmation of this investment means the company will remain in Hessen.